Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America.
The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline.
Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).
Inclusion Criteria:
Exclusion Criteria:
Ciudad Autónoma de Bs As, C1426ABP, Argentina
Ciudad Autónoma de BsAs, C1406FWY, Argentina
Ciudad de Buenos Aires, C1405CWB, Argentina
University of Sydney, New South Wales 2006, Australia
Århus C, 8000, Denmark
Frederiksberg C, 1958, Denmark
University of Helsinki, 00014, Finland
Saint Ingbert, 66386, Germany
Shatin, New Territories, Hong Kong
Kerala, 682026, India
Hengelo OV, 7555 DL, Netherlands
Belgrade, 11000, Serbia and Montenegro